RESUMEN
Reduced cigarette smoke exposure in adult smokers switching from a conventional cigarette (CC) to a potential exposure-reduced electrically heated cigarette smoking system (EHCSS) and no smoking (NS) improved exercise performance. The effects of reduced smoke exposure on the prognostic parameters heart rate (HR) and rate-pressure-product (RPP) were investigated. A total of 18 male adult CC-smokers were randomized in a 3-period cross-over study to CC, EHCSS, or to NS for 3 days each before performing spiroergometry. Exposure parameters declined from CC to EHCSS and to NS. Resting HR and RPP increased from NS to EHCSS and to CC. Chronotropic response/HR recovery were more pronounced in NS than in EHCSS and CC. RPPmax was similar in NS and EHCSS and lowest during CC. Reduced tobacco smoke exposure for 3 days improved the prognostic parameters HR and RPP in an apparently dose-dependent manner.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Cese del Hábito de Fumar , Fumar/efectos adversos , Contaminación por Humo de Tabaco/efectos adversos , Adulto , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Prueba de Esfuerzo , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Método Simple Ciego , Fumar/fisiopatología , Espirometría , Factores de TiempoRESUMEN
The study was carried out as an open-label, but laboratory-blind, single-dose, single-centre, randomized, two-period crossover study. Twenty-two patients with iron deficiency anemia completed the study. The study consisted of two treatment phases of 36 h, separated by a washout period of between 6 and 14 days. The two treatments were given orally. The reference treatment was tetracycline (CAS 60-54-8) alone (2 x 250 mg capsules) and the test treatment was iron(III)-hydroxide polymaltose complex (IPC, Maltofer) together with tetracycline (2 x 250 mg capsules). IPC had no pharmacokinetic effect on the rate of absorption of tetracycline. With concomitant administration of tetracycline and IPC sufficiently high tetracycline concentrations, to ensure bacteriostasis, will be reached. An inhibitor effect of IPC to the tetracycline absorption, as it is known for ferrous salts, could not be observed.
Asunto(s)
Anemia Ferropénica/metabolismo , Antibacterianos/farmacocinética , Compuestos Férricos/efectos adversos , Tetraciclina/farmacocinética , Adulto , Algoritmos , Anemia Ferropénica/sangre , Anemia Ferropénica/tratamiento farmacológico , Área Bajo la Curva , Interacciones Farmacológicas , Femenino , Compuestos Férricos/farmacocinética , Compuestos Férricos/uso terapéutico , Semivida , Humanos , Absorción Intestinal/efectos de los fármacos , Masculino , Persona de Mediana Edad , Control de Calidad , Tamaño de la Muestra , Método Simple CiegoRESUMEN
The study was carried out as an open-label, laboratory-blind, single-dose, randomized, two-period crossover, isotope efficacy study. Twenty-two patients with iron-deficiency anemia were enrolled in the study. The study consisted of two treatment phases of 15 days each, including blood sample measurements for Fe-59 activity. The 2 treatments were given orally. Treatment A was Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer), equivalent to 100 mg elemental iron given orally, and Treatment B consisted of Treatment A combined with 600 mg aluminium hydroxide (CAS 21645-51-2) (10 ml). No differences between the two treatment groups with regard to the erythrocyte uptake were found, and thus IPC can be used with aluminium hydroxide, if necessary.
Asunto(s)
Hidróxido de Aluminio/farmacología , Anemia Ferropénica/tratamiento farmacológico , Antiácidos/farmacología , Compuestos Férricos/farmacocinética , Compuestos Férricos/uso terapéutico , Hierro/farmacocinética , Adolescente , Adulto , Algoritmos , Animales , Área Bajo la Curva , Disponibilidad Biológica , Fenómenos Químicos , Química Física , Suplementos Dietéticos , Método Doble Ciego , Eritrocitos/efectos de los fármacos , Eritrocitos/metabolismo , Femenino , Compuestos Férricos/efectos adversos , Ferritinas/sangre , Humanos , Absorción Intestinal/efectos de los fármacos , Radioisótopos de Hierro , Masculino , Ratones , Persona de Mediana Edad , Control de Calidad , RatasRESUMEN
The study was carried out as an open-label, laboratory-blind, single-dose, randomized, two-period crossover, isotope efficacy study. Twenty-two patients with iron-deficiency anemia were enrolled in the study. The study consisted of two treatment phases of 15 days each, including blood sample measurements for Fe-59 activity. The two treatments were given orally. Treatment A was Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron given orally. Treatment B consisted of Fe-59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl (CAS 64-75-5) given orally. No differences between the two treatment groups with regard to the erythrocyte iron uptake were found, and thus IPC can be used with tetracycline, if necessary.